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Influenza virus infections remain a major and recurrent public health burden. The intrinsic
ever-evolving nature of this virus, the suboptimal efficacy of current influenza inactivated
vaccines, as well as the emergence of resistance against a limited antiviral arsenal,
highlight the critical need for novel therapeutic approaches. In this context, the aim
of this study was to develop and validate an innovative strategy for drug repurposing
as host-targeted inhibitors of influenza viruses and the rapid evaluation of the most
promising candidates in Phase II clinical trials. We exploited in vivo global transcriptomic
signatures of infection directly obtained from a patient cohort to determine a shortlist
of already marketed drugs with newly identified, host-targeted inhibitory properties
against influenza virus. The antiviral potential of selected repurposing candidates was
further evaluated in vitro, in vivo, and ex vivo. Our strategy allowed the selection of a
shortlist of 35 high potential candidates out of a rationalized computational screening
of 1,309 FDA-approved bioactive molecules, 31 of which were validated for their
significant in vitro antiviral activity. Our in vivo and ex vivo results highlight diltiazem, a
calcium channel blocker currently used in the treatment of hypertension, as a promising
option for the treatment of influenza infections. Additionally, transcriptomic signature
analysis further revealed the so far undescribed capacity of diltiazem to modulate the
expression of specific genes related to the host antiviral response and cholesterol
metabolism. Finally, combination treatment with diltiazem and virus-targeted oseltamivir
neuraminidase inhibitor further increased antiviral efficacy, prompting rapid authorization
for the initiation of a Phase II clinical trial. This original, host-targeted, drug repurposing
strategy constitutes an effective and highly reactive process for the rapid identification
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of novel anti-infectious drugs, with potential major implications for the management
of antimicrobial resistance and the rapid response to future epidemic or pandemic
(re)emerging diseases for which we are still disarmed.
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INTRODUCTION
Besides their well-known pandemic potential, annual outbreaks
caused by influenza viruses account for several million
respiratory infections and 250,000 to 500,000 deaths worldwide
(1). This global high morbidity and mortality of influenza
infections represents a major and recurrent public health threat
with high economic burden. In this context, the suboptimal
vaccine coverage and efficacy, coupled with recurrent events
of viral resistance against a very limited antiviral portfolio,
emphasize an urgent need for innovative treatment strategies
presenting fewer obstacles for their clinical use (2).
For decades, the strategy for antiviral development was
mostly based on serial screenings of hundreds of thousands
of molecules to identify “hits” and “leads” that target specific
viral determinants, a quite costly and time-consuming process.
However, the dramatic reduction in successful candidate
identification over time (3), along with a concomitant increase
of regulatory complexity to implement clinical trials, have
fostered rising interest in novel strategies. Indeed, new
approaches, focused on targeting the host instead of the
virus, as well as on marketed drug repurposing for new
antiviral indications (3–5) have been recently proposed in
the context of global health emergencies posed by Ebola (6)
and Zika (7) viruses. Such innovative strategies are strongly
supported by a shift of paradigms in drug discovery, from
“one-drug-one-target” to “one-drug-multiple-targets” (8). In
that sense, different in silico approaches based on structural
bioinformatic studies (9, 10), systems biology approaches (11),
and host gene expression analyses (12) have been applied
to decipher multi-purpose effects of many US Food and
Drug Administration (FDA)-approved drugs. Additionally,
as successfully demonstrated in antiretroviral therapy (13),
targeting host instead of viral determinants may confer a
broad-spectrum antiviral efficacy, and also reduce the risk
of emergence of drug resistance against influenza viruses
(14). As a result, the last decade has witnessed several
host-directed experimental approaches against influenza
infections, notably nitazoxanide, DAS181 or acetylsalicylic acid
(15–17).
In line with this emerging trend, we previously postulated
that host global gene expression profiling can be considered as
a “fingerprint” or signature of any specific cell state, including
during infection or drug treatment, and hypothesized that
the screening of databases for compounds that counteract
virogenomic signatures could enable rapid identification of
effective antivirals (18). Based on this previous proof-of-concept
obtained from in vitro gene expression profiles, we further
improved our strategy by analyzing paired upper respiratory
tract clinical samples collected during the acute infection and
after recovery from a cohort of influenza A(H1N1)pdm09-
infected patients and determined their respective transcriptomic
signatures. We then performed an in silico drug screening
using Connectivity Map (CMAP), the Broad Institute’s publicly
available database of more than 7,000 drug-associated gene
expression profiles (19, 20), and identified a list of candidate
bioactive molecules with signatures anti-correlated with those
of the patient’s acute infection state (Figure 1A). The potential
antiviral properties of selected FDA-approved molecules were
firstly validated in vitro, and the most effective compounds
were further compared to oseltamivir for the treatment of
influenza A(H1N1)pdm09 virus infections in both C57BL/6 mice
and 3D reconstituted human airway epithelia. Altogether, our
results highlight diltiazem, a calcium channel blocker with so far
undescribed capacity to stimulate the epithelial antiviral defense,
as a promising repurposed host-targeted inhibitor of influenza
infection.Moreover, our results plead in favor of the combination
of diltiazem with the virus-targeted antiviral oseltamivir for the
improvement of current anti-influenza therapy, and possibly
decreasing the risk of antiviral resistance. This study confirms
the feasibility and interest of integrating clinical virogenomic
and chemogenomic inputs as part of a drug repurposing
strategy to accelerate bedside-to-bench and bench-to-bedside
drug development.
MATERIALS AND METHODS
Ethics Approval and Consent to Participate
Adult patients were recruited by general practitioners in the
context of a previously published randomized clinical trial
Escuret et al. (21) (ClinicalTrials.gov identifier NCT00830323)
and all of them provided written informed consent. The study
protocol was approved by the Lyon Ethics Committee (Comité
de Protection des Personnes Lyon B) on September 9th, 2009 and
conducted in accordance with the Declaration of Helsinki.
All animal procedures were approved by the Institutional
Animal Care Committee of the Center Hospitalier Universitaire
de Québec (CPAC protocol authorization #2012-068-3)
according to the guidelines of the Canadian Council on Animal
Care.
Clinical Samples
A previously published randomized clinical trial
(ClinicalTrials.gov identifier NCT00830323) was conducted
in Lyon and Paris (France) during the peak circulation of the
influenza A(H1N1)pdm09 virus, with the aim to assess the
efficacy of oseltamivir-zanamivir combination therapy compared
with oseltamivir monotherapy (21). Briefly, patients tested
positive for influenza A infection by the QuickVue rapid antigen
kit (Quidel) were randomized in one of the two treatment
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FIGURE 1 | From nasal wash clinical samples to a shortlist of 35 candidate molecules. (A) Overview of the in silico strategy used in this study. A detailed description
of the strategy is described in the Online Methods section. (B) Hierarchical clustering and heatmap of the 1,117 most differentially deregulated genes between
“infected” (red) and “cured” (light green) samples. Raw median centered expression levels are color coded from blue to yellow. Dendrograms indicate the correlation
between clinical samples (columns) or genes (rows). (C) Functional cross-analysis of candidate molecules obtained from Connectivity Map (CMAP). Three lists of
candidate molecules were obtained using different set of genes in order to introduce functional bias and add more biological significance to this first screening: a Main
List based on the complete list of differentially expressed genes, and two other lists (List #1 and #2) based on subsets of genes belonging to significantly enriched
Gene Ontology (GO) terms. (D) Venn Diagram comparing the total 160 molecules obtained from the three lists described in (C), with monensin as the only common
molecule. Only the candidates selected for in vitro screening and validation are depicted.
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groups and nasal wash specimens were collected within 2 h of
the first visit and every 24 h until 96 h after treatment initiation.
Nasal swabs were also performed on days 5 and 7. In voluntary
patients, an optional supplementary nasal wash was performed
at least 3 months after influenza infection (recovery phase).
H1N1 subtype was further confirmed by PCR. For nine of these
patients, transcriptomic data were obtained from paired samples
collected during influenza infection without treatment and in
the recovery phase.
Sample Processing, RNA Preparation and
Hybridization
Nasal wash samples were collected in RNAlater R© Stabilization
Solution (Thermo Fisher Scientific). Total RNA was extracted
using RNeasy Micro kit (Qiagen) following the manufacturer’s
instructions. RNA quality was assessed using a Bioanalyzer2100
(Agilent technologies, Inc, Palo Alto, CA, USA). To account
for samples having low amount and/or partially degraded
RNA (RNA Integrity Numbers between 1 and 8), we applied
two types of corrections: (i) cRNA labeling was performed
after a linear amplification protocol, as previously described
(22) and (ii) raw signals obtained after hybridization of
labeled cRNA on microarray and data acquisition were
processed using the MAXRS algorithm (23). Labeled cRNA were
hybridized on Affymetrix HG-U133plus2 microarrays according
to manufacturer’s instructions in a GeneChip R© Hybridization
Oven 640 (Affymetrix) and microarrays were subsequently
scanned in an Affymetrix 3000 7G scanner.
Data Normalization and MAXRS
Computational Analysis
The MAXRS algorithm (23) is particularly suited to gene
expression analysis under low hybridization conditions. Briefly,
this method takes advantage of the specific design of Affymetrix
probe sets, which are composed of an average of 11 different
probes that target the same locus, and is based on the observation
that for most of the probe sets the same probe shows the
highest fluorescence intensity in almost all arrays. For each
microarray (m = 1..M) and for each probeset (t = 1..T),
fluorescence intensity values on microarray m of all probes (p
= 1..Pt) belonging to the probeset t are sorted in increasing
order. These ranks are denoted as rmtp. Then, we calculated
across all microarrays the rank sum (RStp) for each probeset t
for each probe p belonging to the probeset t. Finally, for each
probeset t, we kept the three probes p with the highest RStp.
The mean intensity of these three probes is attributed to the
probeset t. As it is common practice with many modern pre-
processing algorithms, and because of the low global fluorescence
signal intensity, mismatched probes were excluded fromMAXRS
analysis.
After pre-processing the raw dataset with the MAXRS
algorithm, a normalization step was performed using Tukey
median-polish algorithm (24). Differential expression was
assessed by applying a Student t-test for each probeset, and
multiple testing was corrected using the Benjamini-Hochberg
algorithm in the qvalue library (25). For further downstream
analysis, genes were selected according to two criteria: (i)
absolute fold change >2, and (ii) corrected p-value < 0.05.
Data were generated according to the Minimum Information
About a Microarray Experiment guidelines and deposited in
the National Center for Biotechnology Information’s Gene
Expression Omnibus (GEO) (26) under accession number
GSE93731.
Functional Analysis
Functional enrichment analysis was performed on a selection of
differentially-expressed genes with DAVID tools (27), using the
Gene Ontology (GO) (28). To further select genes for the CMAP
query, we selected 6 Biological Process (BP) terms (GO_BP:
GO:0009615-response to virus; GO:0006955-immune response;
GO:0042981-regulation of apoptosis; GO:0006952-defense
response; GO:0009611-response to wounding; GO:0042127-
regulation of cell proliferation) that shared >90% of genes
with all significantly enriched GO_BP terms, and 3 relevant
Cellular Component terms (GO_CC: GO:0031225-anchored to
membrane; GO:0005829-cytosol; GO:0005654-nucleoplasm). To
visualize and compare the different lists of compounds, Venn
diagrams were obtained using the webtool developed by Dr. Van
de Peer’s Lab at Ghent University (http://bioinformatics.psb.
ugent.be/webtools/Venn/).
Cells and Viruses
Human lung epithelial A549 cells (ATCC CCL-185) were
maintained in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% fœtal calf serum and supplemented with
2mM L-glutamine (Sigma Aldrich), penicillin (100 U/mL), and
streptomycin (100µg/mL) (Lonza), maintained at 37◦C and 5%
CO2. MucilAir
R© human airway epithelia (HAE) were obtained
from Epithelix SARL (Geneva, Switzerland) and maintained in
air-liquid interphase with specific MucilAir R© Culture Medium
in Costar Transwell inserts (Corning, NY, USA) according to the
manufacturer’s instructions.
Influenza viruses A/Lyon/969/09 and A/Quebec/144147/09
were produced in MDCK (ATCC CCL-34) cells in EMEM
supplemented with 2mM L-glutamine (Sigma Aldrich),
penicillin (100 U/mL), streptomycin (100µg/mL) (Lonza) and
1µg/mL trypsin. Viral titers in plaque forming units (PFU/ml)
and tissue culture infectious dose 50% (TCID50/mL) were
determined in MDCK cells as previously described (29, 30).
Viral Growth Assays
For viral growth assays in the presence of molecules, A549 cells
were seeded 24 h in advance in multi-well 6 plates at 1.8 × 105
cells/well. Three treatment protocols were evaluated. (1) In pre-
treatment protocol, cells were washed with DMEM and then
incubated with different concentrations of candidate molecules
diluted in DMEM supplemented with 2mM L-glutamine (Sigma
Aldrich), penicillin (100 U/mL), streptomycin (100µg/mL)
(Lonza) and 0.5µg/mL trypsin. Six hours after treatment,
cells were washed and then infected with A/Lyon/969/09
(H1N1)pdm09 virus at a multiplicity of infection (MOI) of 0.1.
(2) In pre-treatment plus post-treatment protocol, cells were
initially treated and infected in the same conditions as explained
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above. One hour after viral infection, a second identical dose
of candidate molecules in supplemented DMEM was added.
(3) In post-treatment protocol, cells without pre-treatment
were infected in the conditions described and treatments
with candidate molecules at the indicated concentrations were
initiated 24 h p.i. In all cases, supernatants were collected at 48 h
p.i. and stored at−80◦C for TCID50/ml viral titration.
Viability and Cytotoxicity Assays
Cell viability was measured using the CellTiter 96 R© AQueous
One Solution Cell Proliferation Assay (MTS, Promega). A549
cells were seeded into 96-well plates and treated with different
concentrations of molecules or solvents. Cells were incubated
at 37◦C and 5% CO2 and then harvested at different time-
points, following the same scheme as in viral growth assays.
Results were presented as a ratio of control values obtained with
solvents. Treatment-related toxicity in HAE was measured using
the Cytotoxicity Detection KitPLUS (LDH, Roche) according
to the manufacturer’s instructions. Briefly, duplicate 100 µL-
aliquots of basolateral medium from treated and control HAEs
were incubated in the dark (room temperature, 30min) with 100
µL of lactate dehydrogenase (LDH) reagent in 96-well plates.
After incubation, “stop solution” was added and the absorbance
was measured in a conventional microplate ELISA reader. The
photometer was set up for dual readings to determine non-
specific background at 750 nm, and absorbance was measured
at 490 nm. Percent cytotoxicity was calculated as indicated by
the manufacturer, using mock-treated and 1% triton-treated
epithelia as “low” and “high” controls, respectively. Percent
viability is presented as 100–percent cytotoxicity.
Mouse Model of Viral Infection
All protocols were carried out in seven to 9-weeks old female
C57BL/6N mice (Charles River, QC, Canada). Animals were
randomized in groups of 15 according to their weight to
ensure comparable median values on each group, and then
housed in micro-isolator cages (5 animals per cage) in a
biosafety 2 controlled environment (22◦C, 40% humidity, 12:12 h
photoperiods), with ad libitum access to food and water.
On day 0, mice were lightly anesthetized with inhaled
3% isoflurane/oxygen, and then infected by intranasal (i.n.)
instillation of influenza A/Quebec/144147/09 (H1N1)pdm09
virus in 30 µl of saline, as specified in each case. Control
animals were mock-infected with 30 µl of saline. Candidate
molecules were evaluated in two different treatment protocols:
(i) treatments were started on the same day of infection (day
0, 6 h prior to infection), or (ii) treatments were started 24 h
after infection (day 1). Regardless of treatment initiation time, all
treatments were performed per os (150-µl gavage) once daily for
5 consecutive days (5 drug administrations in total). Mortality,
body weight and clinical signs such as lethargy and ruﬄed fur
were daily monitored on 10 animals/group for a total of 14 days.
Animals were euthanized if they reached the humane endpoint
of >20% weight loss. The remaining 5 animals/group were
euthanized on day 5 p.i. to measure lung viral titers (LVTs).
Vehicle (saline) or oseltamivir were used as placebo and
positive treatment control, respectively. The oseltamivir dose
(10 mg/kg/day) was adjusted to confer ∼50% protection in
the selected experimental conditions and is considered a good
correlate of half the normal dose of 150 mg/day given to humans
(31). The doses of repurposed candidate molecules were selected
to be in the non-toxic range for mouse studies, according to
published preclinical data for their first therapeutic indication. To
validate this choice in our specific model, potential drug toxicity
was evaluated in mock-infected animals treated with the same
regimens as virus-infected mice.
Pulmonary Viral Titers
In order to evaluate the effect of different treatments on viral
replication, 5 animals per group were euthanized on day 5 p.i.
and lungs were removed aseptically.Mice were randomly selected
from the 3 cages of each group to minimize cage-related bias.
Lungs were homogenized in 1ml of PBS using a bead mill
homogenizer (Tissue Lyser, Qiagen) and debris was pelleted by
centrifugation (2,000 g, 5min). Triplicate 10-fold serial dilutions
of each supernatant were plated on ST6GalIMDCK cells (kindly
provided by Dr. Y. Kawaoka, University of Wisconsin, Madison,
WI) and titrated by plaque assays (29). The investigator was
blinded to group allocation.
Viral Infection in Reconstituted Human
Airway Epithelium (HAE)
For HAE infection experiments, apical poles were gently washed
with warm PBS and then infected with a 100-µL dilution
of influenza A/Lyon/969/09 (H1N1)pdm09 virus in OptiMEM
medium (Gibco, ThermoFisher Scientific) at a MOI of 0.1.
Basolateral pole sampling as well as 150-µL OptiMEM apical
washes were performed at the indicated time points, and then
stored at −80◦C for PFU/mL and TCID50/mL viral titration.
Treatments with specific dilutions of candidate molecules alone
or combined with oseltamivir in MucilAir R© Culture Medium
were applied through basolateral poles. Control HAE were
mock-treated in the same conditions with MucilAir R© Culture
Medium without molecules. All treatments were initiated on
day 0 (5 h after viral infection) and continued once daily for
5 consecutive days (5 drug administrations in total). Variations
in transepithelial electrical resistance (1 TEER) were measured
using a dedicated volt-ohmmeter (EVOM2, Epithelial Volt/Ohm
Meter for TEER) and expressed as Ohm/cm2.
High Throughput Sequencing and
Bioinformatics Analysis
cDNA libraries were prepared from 200 ng of total RNA
using the ScriptseqTM complete Gold kit-Low Input (SCL6EP,
Epicenter), according to manufacturer’s instructions. Each cDNA
library was amplified and indexed with primers provided
in the ScriptSeqTM Index PCR Primers kit (RSBC10948,
Epicenter) and then sequenced as 100 bp paired-end reads.
Prior to sequencing, libraries were quantified with QuBit and
Bioanalyzer2100, and indexed libraries were pooled in equimolar
concentrations. Sequencing was performed on an Illumina HiSeq
2500 system (Illumina, Carlsbad, CA), with a required minimum
of 40 million reads sequenced per sample. Conversion and
demultiplexing of reads was performed using bcl2fastq 1.8.4
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(Illumina). The FastQC software (http://www.bioinformatics.
babraham.ac.uk/projects/fastqc) was used for quality controls of
the raw data. Reads were trimmed using the Trimmomatic (32)
software, with a minimum quality threshold of Q30. Trimmed
reads were pseudo-aligned to the Homo sapiens genome
(GRCh38.p11) using the Kallisto software (33). Statistical analysis
was performed in R3.3.1 with the package EdgeR 3.14.0
(34). Differential expression was calculated by comparing each
condition to the mock using a linear model. The Benjamini-
Hochberg procedure was used to control the false discovery
rate (FDR). Transcripts with an absolute fold change >2 and
a corrected p-value < 0.05 were considered to be differentially
expressed. Enriched pathways and GO terms were assessed with
DAVID 6.8 (27). For visualization purposes, a heatmap and
stacked barplots were constructed in R3.3.1 on mean-weighted
fold changes and association between conditions were assessed
by Spearman correlation analysis.
Statistical Analysis
All experimental assays were performed in duplicate at a
minimum, and representative results are shown unless indicated
otherwise. No statistical methods were used to predetermine
sample size in animal studies, which were estimated according to
previous studies and the known variability of the assays. No mice
were excluded from post-protocol analyses, the experimental
unit was an individual animal and equal variance was assumed.
Kaplan-Meier survival plots were compared by Log-Rank
(Mantel-Cox) test and hazard ratios (HR) were computed by
the Mantel-Haenszel method. Weight loss and viral titers of
all groups were compared by one-way analysis of variance
(ANOVA) with Tukey’s multiple comparison post-test. The
testing level (α) was 0.05. Statistical analyses were performed on
all available data, using GraphPad, Prism 7.
RESULTS
Generation of Clinical Virogenomic Profiles
We determined in vivo transcriptional signatures of infection
from paired nasal wash samples of nine untreated patients,
collected during acute A(H1N1)pdm09 pandemic influenza
infection (“infected”) and at least 3 months later to ensure a
recovery non-infected state (“cured”) (21). The nine patients
from whom transcriptomic data could be obtained constitute a
representative sample of the whole studied cohort, except for
the male sex ratio (Table S1). We combined two strategies to
tackle the characteristic low RNA amount/quality of this type
of clinical samples. Firstly, cRNA labeling was performed after
a linear amplification of initial RNA, as previously described
(35). Secondly, raw signals obtained after hybridization of labeled
cRNA on microarray and data acquisition were processed using
the MAXRS algorithm (23) to overcome low hybridization
conditions. This approach, initially developed for the analysis
of heterologous hybridizations, takes advantage of the specific
design of the Affymetrix R© microarray used in our study, with
several probes targeting the same locus (23).
After normalization, differentially expressed genes were
selected based on two criteria: (i) an absolute fold change
>2, and (ii) a Benjamini-Hochberg corrected p-value < 0.05.
We therefore identified a total of 1,117 commonly deregulated
probes, with almost equal proportion of up-regulated (48.4%; n=
541) and down-regulated probes (51.7%; n = 576). Remarkably,
despite considerable inter-patient variability among recovery
state samples, a substantial homogenization of transcriptional
profiles was observed in the context of infection, as shown
in the heatmap presented in Figure 1B and by the median
Spearman’s ρ correlation values for both groups (0.60 “cured”
vs. 0.90 “infected”). These virogenomic signatures of infection
constituted the input for the subsequent in silico query for the
identification of candidate compounds.
In silico Cross-Analysis of Chemogenomic
vs. Virogenomic Clinical Profiles
We then performed an in-silico search for molecules that
reverse the virogenomic signature of infection, using the
CMAP database (Build 02) as previously described (18).
CMAP is a collection of genome-wide transcriptional expression
data from cultured human cells treated with bioactive small
molecules. HG-U133plus2 probesets were mapped to the U133A
probesets using the Ensembl BioMarts online tool (36, 37),
and connectivity scores and p-values were obtained using the
CMAP algorithm (19, 20). With the global set of 1,000 most
differentially expressed genes as input (Figure 1C, Main List),
we obtained a preliminary list of 60 candidate compounds.
In parallel, we used two other subsets of genes belonging
to significantly enriched Gene Ontology (GO) terms obtained
from microarray analyses to introduce functional bias and add
more biological significance to our first screening. Hence, by
using 6 Biological Process terms (GO_BP) that shared more
than 90% of genes (Figure 1C, Functional cross-analysis #1),
a second list of 109 compound candidates was obtained. A
third list of 19 compounds was obtained using 3 relevant
Cellular Component terms (GO_CC) (Figure 1C, Functional
cross-analysis #2). The comparison of the 160 compounds
from the three distinct lists (12.2% of compounds of CMAP,
Table S2) highlighted monensin as the only common compound
(Figure 1D).
To rationally reduce the number of drug candidates,
bioactive drugs were excluded if not compatible with a
final use as antiviral, mostly for safety (e.g., teratogens,
intercalating agents), and/or pharmacological (e.g., documented
low bioavailability) reasons, based on clinical data and the
PubMed/PubChem databases. Thus, the number of candidates
was initially decreased to 139 and then to 110 (Figure S1).
We subsequently determined a shortlist of 35 bioactive
molecules (<3% of CMAP, Table 1) for in vitro screening,
based on two main criteria: (i) molecules representative
of the different pharmacological classes identified, and (ii)
molecules evenly distributed in the three lists obtained after
in silico screening (Main List, List #1 and List #2, Figure 1D),
which comprise a panoply of documented pharmacological
classes, including anti-fungal agents (e.g., monensin, flucytosine),
anti-inflammatory agents (e.g., felbinac, apigenin, prednisone)
and adrenergic agonists/antagonists (timolol, methoxamine,
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TABLE 1 | Shortlist of the 35 selected molecules and their documented pharmacological classes.
Name Pharmacological class
Adiphenine Parasympatholytics/Anticholinergics/Antispamodics
Alpha-estradiol* 5 alpha-reductase inhibitors/Androgenic alopecia treatment
Amiloride*# Epithelial Sodium Channel Blockers/Diuretics/Acid Sensing Ion Channel Blockers
Apigenin*# Anti-Inflammatory Agents, Non- steroidal/?
Benzathine benzylpenicillin# Anti-Bacterial Agents
Biperiden* Antiparkinson Agents/Muscarinic Antagonists/Parasympatholytics
Carmustine Antineoplastic Agents, Alkylating
Chloropyramine Histamine H1 Antagonists
Clofilium tosylate Anti-Arrhythmia Agents
Diltiazem Antihypertensive Agents/Calcium Channel Blockers/Cardiovascular Agents/Vasodilator Agents
Diphenhydramine Anesthetics, Local/Anti-Allergic Agents/Antiemetics/Histamine H1 Antagonists/Hypnotics and Sedatives
Etilefrine Adrenergic beta-1 and alpha agonist/Cardiotonic/antihypotensive agent.
Felbinac# Anti-Inflammatory Agents, Non-steroidal
Flucytosine*# Antifungal Agents/Antimetabolites
Folic acid Hematinics/Vitamin B Complex
Fusidic acid# Anti-Bacterial Agents/Protein Synthesis Inhibitors
Genistein Anticarcinogenic Agents/Phytoestrogens/Protein Kinase Inhibitors
Gentamicin# Anti-Bacterial Agents/Protein Synthesis Inhibitors
Lanatoside C Anti-Arrhythmia Agents
Levamisole* Adjuvants, Immunologic/Antinematodal Agents/Antirheumatic Agents
Methoxamine Adrenergic alpha-1 Receptor Agonists/Sympathomimetics/Vasoconstrictor Agents
Monensin*# Antifungal Agents/Antiprotozoal Agents/Coccidiostats/Proton Ionophores/Sodium Ionophores
Nimesulide*# Anti-Inflammatory Agents, Non-steroidal/Cyclooxygenase Inhibitors
Pindolol Adrenergic beta-Antagonists/Antihypertensive Agents/Serotonin Antagonists/Vasodilator Agents
Prednisone# Anti-Inflammatory Agents/Antineoplastic Agents, Hormonal/Glucocorticoids
Prestwick-1103# Anti-Inflammatory Agents, Non-steroidal/Cyclooxygenase Inhibitors
Ranitidine Anti-Ulcer Agents/Histamine H2 Antagonists
Ribavirin* Antimetabolites/Antiviral Agents
Riboflavin* Photosensitizing Agents/Vitamin B Complex
Roxithromycin# Anti-Bacterial Agents
Sulfadimethoxine# Anti-Infective Agents
Sulfamonomethoxine# Anti-Infective Agents
Timolol* Adrenergic beta-Antagonists/Anti-Arrhythmia Agents/Antihypertensive Agents
Tolazoline Adrenergic alpha-Antagonists/Antihypertensive Agents/Vasodilator Agents
Ursodeoxycholic acid Cholagogues and Choleretics
Shortlist of the 35 selected candidates representative of the 110 molecules obtained from the in silico screening (Figure 1 and Figure S1). Documented pharmacological classes were
obtained from PubChem (https://pubchem.ncbi.nlm.nih.gov). (*) indicate molecules previously evaluated for their antiviral properties according to the literature, and numerals (# ) those
belonging to anti-microbial or anti-inflammatory related pharmacological classes.
tolazoline), as represented in the Venn diagram (Figure 1D,
Table 1). Interestingly, at least 14 (40%) molecules from our
short-list belong to a pharmacological class related with anti-
microbial or anti-inflammatory activities (Table 1, #), and 11
(31.4%) have already been reported in the literature for their
antiviral properties against influenza or other viruses (Table 1, ∗),
notably the nucleoside inhibitor ribavirin (38, 39) and the
ionophore monensin (40).
Inhibitory Effect of the Selected Molecules
on A(H1N1)pdm09 Viral Growth in vitro
In vitro screening of the antiviral potency of the 35 selected
molecules was performed in A549 human lung epithelial cells
seeded in 6-well plates. Firstly, we evaluated the impact of
6 h pre-treatment with a 10-fold drug concentration range,
using the original CMAP concentration as reference. Six
hours after treatment, cells were washed and infected with
influenza A(H1N1)pdm09 virus at a MOI of 0.1. Viral titers
in supernatants collected from treated samples at 48 h post
infection (p.i.) were normalized with those measured in
mock-treated controls (>105 TCID50/mL). Potential treatment-
induced cell toxicity was evaluated in the same experimental
conditions using the MTS assay and expressed also as the
percentage of cell viability compared to non-infected controls
(Figure 2). Based on antiviral activity and cell viability profiles
obtained (Figure 2A, blue triangles), we defined as “inhibitors”
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FIGURE 2 | Screening and validation of the effect of selected molecules on A(H1N1)pdm09 viral growth in vitro. (A, left) Evaluation on A549 cells of the antiviral
potency of the 35 candidates selected by in silico analysis. Relative viral production (%, X axis) and relative cell viability (%, Y axis) of both pre-treatment (blue triangles)
and pre-treatment/treatment (green circles) regimens were evaluated. A 10-fold drug concentration range using CMAP as reference (CMAP × 10, CMAP, CMAP/10,
CMAP/100, CMAP/1,000, and CMAP/10,000) was used. CMAP × 10 was only tested in the context of pre-treatment, by anticipation of a lower efficacy of molecules
in this experimental setup. All experimental assays were performed in triplicate and mean values are represented. (A, right) Zoom panels depicting molecules defined
(Continued)
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FIGURE 2 | as “inhibitors” according to the following two criteria: (i) induce a 75% or higher reduction on viral production, and (ii) have minor impact on cell viability,
with relative values in the 90–110% range. For clarity purposes, with the exception of diltiazem, etilefrine, monensin, and ribavirin. Ad, Adiphenine; Al, Alpha-estradiol;
Am, Amiloride; Ap, Apigenin; Be, Benzathine Benzylpenicilline; Bi, Biperiden; Ca, Carmustine; Ch, Chloropyramine; Cl, Clofidium tosylate; Di, Diphenydramine; Fe,
Felbinac; Fl, Flucytosine; Fo, Folic acid; Fu, Fusidic acid; Ge, Genistein; Ga, Gentamycin; La, Lanatoside C; Le, Levamisole; Me, Methoxamine; Ni, Nimesulide; Pi,
Pindolol; Po, Prednisone; Pr, Prestwick-1103; Ra, Ranitidine; Ri, Riboflavine; Ro, Roxythromycin; Sud, Sulfadimethoxine; Sum, Sulfamonomethoxine; Ti, Timolol; To,
Tolazoline; Us, Urseodeoxycholic acid. Dose-response curves for all the 35 molecules are presented in Table S3. (B) Venn diagram of the 10 molecules identified in
pre-treatment (10/35; 28.57%) and matching the “inhibitor” criteria, mainly when used at 10-fold CMAP concentration. EC50 curves for monensin and ranitidine are
represented. (C) Venn diagram of the 30 “inhibitor” molecules identified in pre-treatment/treatment (30/35; 85.7%). EC50 curves for monensin, diltiazem, and etilefrine
are represented.
compounds that fulfilled the following two criteria: (i) induce
>75% reduction on viral production, and (ii) have minor
impact on cell viability, with relative values in the 90–110%
range (Figure 2A, squares in left panels and zooms in right
panels). A total of 10 compounds (28.6%) matched both
criteria, mainly when used at a 10-fold CMAP concentration
(Figure 2B), yet only a limited number of them exhibited
classic dose-dependent inhibition. Whenever possible, as in
the case of monensin or ranitidine for example, EC50 values
were calculated, which were mostly in the micromolar range
(Figure 2B).
In a second round of screening, we tested the same
6 h pre-treatment but with serial 10-fold dilutions from the
initial CMAP concentration to CMAP/10,000, followed by one
additional treatment immediately after infection (Figure 2A,
green circles in left and right panels). In these conditions,
30 compounds (85.7%) met our criteria to be considered as
inhibitors of viral production (Figure 2C), with half of them
showing a classic dose-dependent inhibition effect. Calculated
EC50 values were in the nanomolar range and hence significantly
lower than those calculated in the context of pre-treatment
only. Dose response curves and calculated EC50 for all the
35 compounds are presented in Figure S2 and Table S3,
respectively.
Efficacy of Selected Molecules for the
Treatment of Influenza A(H1N1)pdm09
Virus Infection in Mice
Based on EC50 and cytoxicity data from the in vitro screening,
we selected 8 molecules to investigate their potential as
inhibitors of influenza A(H1N1)pdm09 in C57BL/6 mice.
Oseltamivir, the standard antiviral for the treatment of
influenza infections was used as control. All treatments
were performed per os, starting 6 h before infection and
being continued once daily for 5 consecutive days (5 drug
administrations in total) (Figure 3). While animals treated
with oseltamivir or monensin showed clinical improvement
compared to the saline (placebo) group in terms of survival
and weight loss (oseltamivir only), treatment with Lanatoside
C, prednisolone, flucytosine, felbinac, and timolol showed no
clinical benefit at the selected concentrations (Figure S3A). In
contrast, diltiazem and etilefrine not only significantly improved
survival and maximum mean weight losses (Figures 3A,B),
but also showed at least 1-log reductions in LVTs on day
5 p.i. (Figure 3C). Importantly, no signs of toxicity were
observed for any of the drugs at the regimens tested
(Figure S3B).
Diltiazem Retains Its in vivo Efficacy When
Administered 24h After Viral Infection
To best mimic the therapeutic setting, we next evaluated
the efficacy of the same 5-day oral regimen with diltiazem
or etilefrine but when initiated 24 h after viral infection
(Figure 4). As with oseltamivir and monensin, diltiazem
treatment completely prevented mortality and reduced weight
loss in influenza A(H1N1)pdm09 infected mice, which otherwise
showed only 50% (5/10) survival for the etilefrine and saline
groups (Figures 4A,B). Interestingly, 1- to 1.5-log reductions in
LVTs compared to the saline group were observed at day 5 in
groups of mice treated with diltiazem or etilefrine (Figure 4C).
We then used a more stringent approach by increasing the viral
inoculum to evaluate the same delayed (24 h post infection)
5-day diltiazem regimen in the context of a 100% lethal
A(H1N1)pdm09 infection (Figures 4D–F). Whereas, treatment
with oseltamivir and diltiazem successfully rescued 40% (4/10)
and 20% (2/10) of mice, respectively, half-dose treatment with
diltiazem (45 mg/kg) rescued 30% (3/10) of mice from death,
also showing significant improvement in mean weight loss
(Figures 4D,E). Calculated hazard ratios (HR) for the saline
group compared to these three treatment groups were 8.41
(CI95: 1.65–43.02), 2.85 (0.56–14.47), and 7.62 (1.49–38.96),
respectively. Noteworthy, LVTs at day 5 p.i. were comparable
among all treated and untreated groups (Figure 4F), suggesting
mainly a protective effect of diltiazem toward severe influenza
infection rather than a direct role in decreasing viral production.
Diltiazem Significantly Reduces Viral
Replication in Infected Reconstituted
Human Airway Epithelia (HAE)
To further complement in vivo data, we characterized the
inhibitory properties of diltiazem using a biologically relevant
reconstituted airway epithelium model, derived from human
primary bronchial cells (MucilAir R©, Epithelix). HAE were
infected with influenza A(H1N1)pdm09 at a MOI of 0.1,
and treatments on the basolateral medium were initiated 5 h
p.i. and continued once daily for 5 consecutive days. Viral
replication at the apical surface of mock-treated (MucilAir R©
Culture Medium without molecules) HAE peaked at 48 h p.i.
(∼1 × 108 PFU/ml) and was detectable at important levels
for at least 7 days. As expected, trans-epithelial electrical
resistance (TEER) values, measuring tight junction and cell
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FIGURE 3 | Efficacy of oral administration of selected molecules in mice infected with influenza A(H1N1)pdm09 virus. C57BL/6N mice (n = 15/group) were
intranasally inoculated with 5 × 105 PFU of influenza A/Quebec/144147/09 virus on day 0 and treated by gavage with saline (gray), oseltamivir 10 mg/kg/day (red),
monensin 10 mg/kg/day (blue), diltiazem 90 mg/kg/day (green), or etilefrine 3 mg/kg/day (orange). A mock-infected, saline-treated group (black dotted line, n = 6)
was included as control. Treatments were initiated on day 0 (6 h before infection) and administered once daily for 5 consecutive days. (A) Survival rates (n = 10/group),
(B) mean weight changes (±SEM, n = 10/group or remaining mice) and (C) median (±CI95, n = 5/group) lung viral titers on day 5 p.i. are shown. *p < 0.05,
compared to the infected saline-treated group by one-way ANOVA with Tukey’s post-test. Data are representative of two independent experiments.
layer integrity, sharply decreased and bottomed out at 72 h
p.i. in the untreated control, correlating with the first virus
detection on the basolateral medium (Figure 5A and Table S6).
A similar pattern was observed in infected HAE treated with
oseltamivir 0.1µM or diltiazem 9µM (CMAP), which conferred
no significant advantage over the untreated control. Conversely,
oseltamivir 1µM and diltiazem 90µM treatments (10-fold
CMAP) strongly inhibited viral replication, delaying the peak
of viral production by 24 h. Both treatments induced >3-log
reductions in apical viral titers at 48 h p.i. compared to the
untreated control, and >2-log reductions when comparing peak
titers (48 h p.i. untreated vs. 72 h p.i. treated). Moreover, whereas
oseltamivir treatment stabilized TEER during the time-course
of infection, diltiazem treatment partially buffered the TEER
decrease observed in the untreated control (Figure 5A and
Table S6). No virus was detected on the basolateral medium
for these two treated groups, and absence of treatment-induced
toxicity was confirmed by measuring the release of intracellular
lactate dehydrogenase (LDH). Interestingly, we observed that
inhibitory and protective properties demonstrated by diltiazem
were progressively reversible when basolateral medium was
replaced with fresh medium without drugs. Overall, these results
are in accordance and strongly support the inhibitory and
protective effects of diltiazem observed in vitro and in mice,
respectively.
Diltiazem-Oseltamivir Combination
Confers Improved Efficacy When
Compared to Monotherapy in Infected HAE
We anticipated that the combination of two antiviral compounds
that target different viral/cellular determinants could induce
better virological and physiological responses when compared
to antiviral monotherapy. We therefore evaluated the diltiazem-
oseltamivir combination in the same conditions described above,
notably a 5-day treatment course with treatment initiation at
5 h p.i. The diltiazem 90 µM/oseltamivir 1µM combination
conferred >3-log reduction in apical peak viral titers when
compared to the untreated control, even greater than that
observed with same dose monotherapy. TEER values remained
stable during combined treatment, comparable to those observed
with oseltamivir 1µM monotherapy (Figure 5B and Table S6).
Remarkably, although not effective as monotherapy in the low
concentrations tested above, the diltiazem 9 µM/oseltamivir
0.1µM combination contrariwise delayed the peak of viral
production, significantly reduced apical viral titers, and slightly
buffered TEER values compared to the untreated control
(Figure 5B and Table S6). Once again, no treatment-related
toxicity was observed for any of the combinations tested.
These results plead in favor of the potential of diltiazem
for the improvement of current anti-influenza therapy with
neuraminidase inhibitors.
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FIGURE 4 | Efficacy of post-infection oral treatment with diltiazem and etilefrine in mice infected with influenza A(H1N1)pdm09 virus. C57BL/6N mice (n = 15/group)
were intranasally inoculated with 1 × 105 (A–C) or 4 × 106 (D–F) PFU of influenza A/Quebec/144147/09 virus on day 0 and treated by gavage with saline (gray),
oseltamivir 10 mg/kg/day (red), monensin 10 mg/kg/day (blue, A only), diltiazem 45 mg/kg/day (light green, B only), diltiazem 90 mg/kg/day (dark green), or etilefrine 3
mg/kg/day (orange, (A) only). A mock-infected, saline-treated group (black dotted line, n = 6) was included as control. Treatments were initiated on day 1 (24 h after
infection and administered once daily for 5 consecutive days. (A,D) Survival rates (n = 10/group), (B,E) mean weight changes (±SEM, n = 10/group or remaining
mice), and (C,F) median (±CI95, n = 5/group) lung viral titers on day 5 p.i. are shown. ***p < 0.001, compared to the infected saline-treated group by one-way
ANOVA with Tukey’s post-test. Data are representative of two independent experiments.
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FIGURE 5 | Diltiazem significantly reduces viral replication in infected reconstituted human airway epithelia (HAE). Apical viral production (±SEM) and transepithelial
electrical resistance (1 TEER±SEM) in MucilAir® human airway epithelium infected on the apical pole with influenza A/Lyon/969/09 (H1N1) pdm09 virus at a MOI of
0.1 and subjected to (A) single or (B) combined treatments by the basolateral pole. Treatments with culture medium (mock, gray), oseltamivir 0.1µM (red, dotted line),
oseltamivir 1µM (red, solid line), diltiazem 9µM (green, dotted line), diltiazem 90µM (green, solid line), oseltamivir 0.1 µM/diltiazem 9µM (brown, dotted line) or
oseltamivir 1 µM/diltiazem 90µM (brown, solid line) were initiated 5 h after infection and administered once daily for 5 consecutive days. **p < 0.01 and ***p < 0.001
compared to the infected Mock-treated group by one-way ANOVA with Tukey’s post-test. Data are representative of three independent experiments.
Diltiazem Treatment Induces a Significant
Reversion of the Viral Infection Signature
Since the rationale behind our approach relies on attaining
antiviral activity through a drug-induced global and multi-level
inversion of the infection signature, we advantageously used
the MucilAir R© HAE model coupled with high-throughput
sequencing in order to characterize and compare the specific
transcriptional signatures induced by infection and/or diltiazem
treatment (Figure 6 and Figure S4). HAE were mock-infected
or infected with influenza A(H1N1)pdm09 virus and then
mock-treated or treated in the same experimental conditions
in which the antiviral effect of diltiazem has been previously
validated (MOI of 0.1, 90µM diltiazem). At 72 h p.i., cells
were lysed and total RNA was extracted. cDNA libraries were
then produced, amplified, and subjected to high-throughput
sequencing. Taking the mock-infected / mock-treated (“mock”)
as baseline, we initially performed DAVID functional gene
enrichment (absolute fold change >2, Benjamini-Hochberg
corrected p < 0.05) on the specific transcriptional signature of
diltiazem with the objective of gaining insight on the putative
host pathways involved in its antiviral effect. The lists of up-
regulated (n = 194) and down-regulated (n = 110) transcripts
in the mock-infected/diltiazem (“mock + diltiazem”) condition
were analyzed using DAVID 6.8 to highlight associations with
specific GO terms. Although no enriched BP was identified
among down-regulated transcripts, the list of up-regulated
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FIGURE 6 | Diltiazem treatment effectively induces significant reversion of the viral infection signature. (A) DAVID gene enrichment analysis of the diltiazem
transcriptional signature. The seven most significant biological processes (BP) are presented. BP related to antiviral response and cholesterol biosynthesis/metabolism
are represented in blue and green, respectively. (B) Hierarchical clustering and heatmap of the 118 common differentially expressed transcripts (absolute fold change
>2, Benjamini-Hochberg corrected p-value < 0.05) between mock-infected/diltiazem (“mock + diltiazem”), infected/mock-treated (“H1N1”), or infected/diltiazem
(“H1N1 + diltiazem”) HAE. The mock-infected/mock-treated (“mock”) condition was used as baseline. Mean-weighted fold changes are color-coded from blue to
yellow. (C) Median Spearman ρ correlation value calculations between the 3 conditions highlighted in the heatmap. (D) Stacked barplot representation of the 40 most
up/down-regulated transcripts highlighted in the analysis. Barplots were constructed in R3.3.1 based on mean-weighted fold changes and ordered according to
H1N1 values (blue). Mock + diltiazem and H1N1 + diltiazem conditions are represented in yellow and green, respectively.
transcripts associated with diltiazem treatment highlighted 7
particularly enriched BP. While 4 of these BP (GO:0009615;
GO:0045071; GO:0051607; GO:0060337) are directly linked
to antiviral response/cellular response to virus, the remaining
3 (GO:0055114; GO:0008299; GO:0006695) are involved in
cholesterol biosynthesis/metabolism (Figure 6A). We then
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compared the common differentially expressed transcript
levels between the three infection/treatment conditions. These
transcriptional signatures revealed a marked anti-correlated
profile between the “mock + diltiazem” and the infected /
mock-treated (“H1N1”) conditions (Figure 6B), supported by
a median Spearman’s ρ correlation value of −0.82 (Figure 6C).
Most important, the infected/diltiazem (“H1N1 + diltiazem”)
condition yielded ρ correlation values of 0.40 and −0.72 when
compared to either “mock + diltiazem” or “H1N1,” respectively,
therefore confirming a partial reversion of the infection
virogenomic signature during effective antiviral treatment with
diltiazem (Figure 6D and Figure S4), as expected.
DISCUSSION
The existing urge for alternative strategies to cope with
the limited efficacy of currently approved antivirals for the
prevention and treatment of influenza infections (2, 41, 42),
mostly in the case of patients with severe influenza and acute
respiratory distress syndrome (ARDS) (43, 44), represented the
central driving force of this study. Here, we developed and
validated for the first time an innovative approach based on
clinical genomic signatures of respiratory viral infections for
the rapid discovery, in vitro, in vivo, and ex-vivo evaluation, as
well as the repurposing of FDA-approved drugs for their newly
identified host-targeted inhibitory and protective properties
against influenza infections.
Targeting host components on which viral replication depends
instead of viral determinants represents a real change of
paradigm in antiviral development, with pioneering results
mainly observed in the context of antiretroviral therapy (13, 45).
Nevertheless, and despite strong putative advantages such as
the achievement of broad-spectrum antiviral efficacy and the
minimization of viral drug resistance, this approach usually fails
to overcome two major limiting factors of classic compound
screening. Firstly, it remains target-centered per se, therefore
leading to the identification of drugs with limited efficacy due to
the complex network and high redundancy of the host cellular
pathways. Secondly, the need of high-throughput screenings
often entails the measurement of a very limited number of
viral parameters, usually in non-physiologically and hence poorly
relevant conditions and/or cellular models.
Based on our initial proof-of-concept study on the in silico
screening of the CMAP database (19, 20) with no initial a priori
on specific host targets (18), we moved our approach up to
the clinical trial setting, by determining exploitable and more
relevant virogenomic profiles directly from standard clinical
samples of influenza-infected patients. Since the low amount of
often degraded RNA obtained from these samples represented
a major challenge, we implemented an original combination of
sample preparation techniques for low input but high quality
samples with data processing initially designed for expression
analysis of non-model species (22, 23).
Another substantial development was the integration of
several lists of candidate molecules issued from different
transcriptomic signatures with enriched relevant DAVID Gene
Ontology terms, and their final selection based on their
pharmacological classes and potential compatibility as antivirals.
Our refined strategy allowed the selection of a shortlist of 35
high potential candidates out of a rationalized computational
screening of a total of 1,309 FDA-approved bioactive molecules.
This drastic positive selection step constituted a major advantage,
since it enabled the implementation of relevant and integrated
in vitro, in vivo and ex-vivo evaluations in a time- and cost-
effective manner. Most important, the use of patient (in vivo)
virogenomic profiles led to the identification of molecules with
highly improved in vitro activity and significant in vivo antiviral
efficacy as compared with compounds previously obtained from
our initial study based on cell culture (in vitro) virogenomic
profiles (18). These results truly highlight the added value of
using relevant clinical virogenomic signatures to optimize the
computational screening for active drugs.
Two of the molecules identified in this study with
transcriptomic profiles that counteract clinical virogenomic
signatures (e.g., ribavirin and monensin) have already been
validated for their anti-influenza properties (38, 40), and then
supported the relevance of our compound selection strategy.
Nevertheless, although different modes of action have been
postulated for the anti-influenza activity of the synthetic
guanosine analog ribavirin (39), the exact mechanisms remain
uncharacterized so far. Similarly, it has been postulated that
monensin, an antibiotic isolated from Streptomyces spp, may have
a role as a ionophore that interferes with intracellular transport
of several enveloped viruses, including influenza (40). In that
sense, even if we cannot rule out that some of the molecules
identified in silico exert a direct effect on a specific pathway or
cellular target, the fact that these molecules have been identified
with a high anti-correlation rate in CMAP strongly supports
a potential multi-target inhibitory effect, probably resulting
in deep modifications of host gene expression. In fact, both
monensin and ribavirin were previously reported to modulate
the host cellular gene expression profile, notably through the
up-regulation of the cholesterol and lipid biosynthesis genes (46)
or the virus-induced ISRE signaling and antiviral ISGs genes
(47), respectively.
The two most promising molecules highlighted in this
study are etilefrine, an alpha and beta- adrenergic receptor
agonist, currently indicated as a cardiotonic and anti-hypotensive
agent (48) and mainly diltiazem, a voltage-gated Ca2+
channel antagonist that is currently used to control angina
pectoris and cardiac arrhythmia (49). In addition to their
strong inhibitory effect on the viral growth of circulating
A(H1N1)pdm09 viruses, with in vitro EC50 values in the
nanomolar range (Figure 2), both molecules also demonstrated
antiviral properties against oseltamivir-resistant A(H1N1)pdm09
and prototype H3N2 and B influenza strains (Table S4).
Interestingly, virus pre-incubation with diltiazem or etilefrine
before infection did not affect final viral titers compared to
PBS-incubated controls, hence suggesting that the observed
antiviral effect of these molecules is not mediated by direct
drug-virus interactions at early stages of viral entry (Table S5).
Our in vivo results (Figures 3, 4), obtained without previous
treatment optimization in terms of dosage or administration
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route, also suggest that these drugs harbor a protective role
toward influenza infection, particularly in the case of diltiazem,
which conferred increased survival in mice even in a model
of severe influenza infection (Figures 4D–F). Moreover, the
inhibitory and protective properties of diltiazem were validated
in the reconstituted human airway epithelium model, also
showing enhanced efficacy when combined with oseltamivir
(Figure 5).
Finally, a very recent study by Fujioka and colleagues (50)
confirmed the antiviral activity of diltiazem anticipated by our
approach. In that study, based on the role of Ca2+ channels
on the attachment of influenza viruses to the host cell, the
authors discuss whether the diltiazem induced modulation of
Ca2+ channel activity might not fully explain such observed
antiviral activity, consistent with a multi-level (off-target) effect
of diltiazem. In this context, in which not all Ca2+ channel
inhibitors confer significant antiviral activity, the newly described
capacity of diltiazem to partially reverse the global virogenomic
signature of infection and modulate specific genes related to the
host antiviral response and cholesterol metabolism (Figures 6
and Figure S4) suggests a putative explanation for its inhibitory
effect observed in vitro, ex vivo and in mice. Nevertheless,
although RT-qPCR mRNA quantification performed on a set
of genes representative of the two hubs further validated these
observations (Figure S5), further investigations are underscored
to shed light on the specific mechanisms underlying such
potential multi-level mode of action of diltiazem.
Overall, the results presented here set a solid baseline for
our drug repurposing strategy and for the use of diltiazem
as a host-targeted antiviral in clinical practice. Moreover, the
increased antiviral efficacy observed in reconstituted human
airway epithelium (Figure 5B and Table S6) plead in favor of
the combination of diltiazem with the virus-targeted antiviral
oseltamivir for the improvement of current anti-influenza
therapy, and possibly decreasing the risk of development of
viral resistance. In that regard, our results prompted a French
multicenter randomized clinical trial aimed at assessing the
effect of diltiazem-oseltamivir bitherapy compared with standard
oseltamivir monotherapy for the treatment of severe influenza
infections in intensive care units, hence completing the bedside-
to-bench and bench-to-bedside cycle of our innovative approach.
Additionally, retrospective signature analysis of sequential
respiratory samples from patients included in both study arms
and stratified according to their clinical response to treatment
will provide valuable data to pursue the investigations on the
specific mediators of the diltiazem-related antiviral response.
This trial (FLUNEXT TRIAL PHRC #15-0442, ClinicalTrials.gov
identifier NCT03212716) is currently ongoing.
Finally, our study underscores the high value of clinical
specimens and the advantages of exploiting virogenomic and
chemogenomic data for the successful systematic repurposing
of drugs already available in our modern pharmacopeia as new
effective antivirals. We propose that our approach targeting
respiratory epithelial cells, the principal influenza infected cell
type in the lung, could be extended to other respiratory viruses
and eventually to other pathogens involved in acute infections.
Importantly, drug repurposing presents several financial and
regulatory advantages compared to the development of de novo
molecules (5), which are of particular interest not only in the
context of antimicrobial resistance but also against both emerging
or recurrent pathogens for which we are still disarmed.
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